与传统的脂质体递送系统相比，用于癌症目的的靶向脂质体系统已被认为是一种特定且稳健的方法。癌细胞具有独特的微环境，其表面有特殊的过表达受体，为利用主动靶向发现新颖有效的药物递送系统提供了机会。智能靶向脂质体，对内部或外部刺激做出反应，通过增加药物的积累来提高递送效率。将抗癌剂封装在肿瘤部位。针对常见细胞表面受体的抗体和适体的应用是一个强大且不断发展的领域。此外，免疫脂质体和癌症疫苗作为辅助化疗也适合有利的免疫调节。组合和多功能系统在这方面也很有吸引力。然而，潜在的活性靶向脂质体药物递送系统要获得临床认可还有很长的路要走，这主要是由于功能化部分的交叉干扰和生物相容性问题。工程脂质体制剂必须根据组织特性进行设计，包括表面化学、电荷和微血管系统。在本文中，我们旨在研究全球常见癌症治疗的最新靶向脂质体系统。

Targeted liposomal systems for cancer intention have been recognized as a specific and robust approach compared to conventional liposomal delivery systems. Cancer cells have a unique microenvironment with special over-expressed receptors on their surface, providing opportunities for discovering novel and effective drug delivery systems using active targeting.Smartly targeted liposomes, responsive to internal or external stimulations, enhance the delivery efficiency by increasing accumulation of the encapsulated anti-cancer agent in the tumor site. The application of antibodies and aptamers against the prevalent cell surface receptors is a potent and ever-growing field. Moreover, immuno-liposomes and cancer vaccines as adjuvant chemotherapy are also amenable to favorable immune modulation. Combinational and multi-functional systems are also attractive in this regard. However, potentially active targeted liposomal drug delivery systems have a long path to clinical acceptance, chiefly due to cross-interference and biocompatibility affairs of the functionalized moieties.Engineered liposomal formulations have to be designed based on tissue properties, including surface chemistry, charge, and microvasculature. In this paper, we aimed to investigate the updated targeted liposomal systems for common cancer therapy worldwide.